About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Alzheimer's and Blood Glucose Levels | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNNCT04614376

Alzheimer's and Blood Glucose Levels

The Alzheimer's and Blood Glucose Levels Study is researching the differences in blood glucose levels between people with and without Mild Cognitive Impairment or Alzheimer's disease with the aim of e...

Lead sponsor: Bio Conscious Technologies Inc.•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Amir Hayeri, MSc

CONTACT

+1-778-986-3030 amir@bioconscious.tech

Sponsors

Lead Sponsor

Bio Conscious Technologies Inc.

This study will collect continuous glucose monitor (CGM) data from participants already using CGMs to better understand the relationship between Alzheimer's Disease and blood glucose levels. This study will use the " Endobits Companion " app for data collection. The Endobits Companion app is freely available for Android and iOS mobile devices, and was designed to keep track of patients diabetes management through a journal and relay this information with their CGM readings to their caring physician.

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•For the case group: have been diagnosed with MCI or AD within the past 5 years.
•For the control group: have not been diagnosed with MCI or AD or another major dementia disease
•Currently using a continuous glucose monitor (CGM).
•Willing and able to provide informed consent, and to have their data collected through the Endobits Companion app. If the participant themself is unable to provide informed consent, it will be sought from their primary caregiver.

Exclusion Criteria

•Patients younger than 50 years of age.
•Patients with a BMI lower than 18 or higher than 35.
•Patients with a major psychiatric illness (e.g., major depressive disorder, schizophrenia, bipolar disorder)
•Patients diagnosed with another major dementia disease, including vascular dementia, Lewy Body disease, Huntington's disease, Creutzfeldt-Jakob disease, and Parkinson's disease.

Related studies

RECRUITINGPhase 3

Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease

NCT07571161 · Alzheimer Disease

RECRUITINGPhase 2

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

NCT06847321 · Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis

Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)

NCT06347315 · Mild Cognitive Impairment

rTMS Combined With Aerobic Exercise for Older Adults With Mild Cognitive Impairment and Comorbid Depression

NCT07652775 · Mild Cognitive Impairment (MCI), Depressive Symptoms

RECRUITINGPhase 3

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229 · Alzheimer Disease, Agitation

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 4, 2020Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment100

Start dateNov 2020

Last updatedNov 4, 2020

Condition

Mild Cognitive Impairment Alzheimer Disease

Locations shown

Bio Conscious Technologies Inc.

Vancouver, British Columbia

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 4, 2020Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions